InvestorsObserver
Sign Up Login

MEDXF Medexus Pharmaceuticals Inc

$1.30 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

MEDXF Stock Analysis Overview

What this means: Medexus Pharmaceuticals Inc (MEDXF) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives MEDXF a rank of 23. Our methodology considers analysis of the company's financial situation and how it has traded recently. MEDXF rank of 23 means that it ranks below 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

MEDXF Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

MEDXF Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

MEDXF Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

MEDXF Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

MEDXF Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

MEDXF Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

MEDXF Stock Analysis Overview

What this means: Medexus Pharmaceuticals Inc (MEDXF) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives MEDXF a rank of 23. Our methodology considers analysis of the company's financial situation and how it has traded recently. MEDXF rank of 23 means that it ranks below 77% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full MEDXF report

MEDXF Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

MEDXF Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

MEDXF Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

MEDXF Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

MEDXF Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

MEDXF Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Medexus Pharmaceuticals Inc (MEDXF) Analyst Forecast

MEDXF Price, Volume, Earnings, and Dividend Date

  • Last Price $1.30
  • Previous Close $1.30
  • Change $0.00
  • Open $1.30
  • Volume 350
  • Avg. Volume (100-day) 17,833
  • Market Cap 31,795,677
  • Days Range 1.3 - 1.3028
  • 52-week Range 0.84 - 2.56
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 5.44
  • EPS 0.34
  • Earnings Date —
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec. Premium
  • Beta 0.773
  • PEG Ratio —

Medexus Pharmaceuticals Inc (MEDXF) Company Description

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Medexus Pharmaceuticals Inc (MEDXF) Stock Chart

View Interactive MEDXF chart

My Watchlists

Top Stocks in Drug Manufacturers - Specialty & Generic